WAVE Life Sciences (NASDAQ:WVE) Hits New 52-Week Low – Here’s What Happened

WAVE Life Sciences Ltd. (NASDAQ:WVE) shares hit a new 52-week low on Wednesday . The company traded as low as $5.01 and last traded at $5.05, with a volume of 6892596 shares traded. The stock had previously closed at $6.07.

Analyst Upgrades and Downgrades

WVE has been the subject of a number of recent analyst reports. Truist Financial started coverage on shares of WAVE Life Sciences in a research note on Wednesday, April 29th. They issued a “buy” rating and a $15.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of WAVE Life Sciences in a research note on Friday, July 17th. UBS Group set a $13.00 target price on shares of WAVE Life Sciences in a report on Monday, August 3rd. New Street Research set a $13.00 target price on shares of WAVE Life Sciences in a research note on Thursday, June 11th. Finally, B. Riley Financial reduced their price target on WAVE Life Sciences from $31.00 to $22.00 and set a “buy” rating for the company in a report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, WAVE Life Sciences currently has a consensus rating of “Moderate Buy” and an average price target of $22.53.

WAVE Life Sciences Stock Performance

The firm has a fifty day simple moving average of $5.91 and a 200-day simple moving average of $8.54. The firm has a market cap of $995.10 million, a price-to-earnings ratio of -4.63 and a beta of -1.26.

WAVE Life Sciences (NASDAQ:WVE) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.04). The company had revenue of $2.27 million during the quarter, compared to analyst estimates of $7.45 million. WAVE Life Sciences had a negative net margin of 309.73% and a negative return on equity of 50.36%. Analysts expect that WAVE Life Sciences Ltd. will post -1.12 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of WVE. Pictet Asset Management Holding SA grew its position in shares of WAVE Life Sciences by 5,024.6% in the fourth quarter. Pictet Asset Management Holding SA now owns 805,901 shares of the company’s stock valued at $13,830,000 after purchasing an additional 790,175 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of WAVE Life Sciences by 152.6% during the first quarter. Renaissance Technologies LLC now owns 597,220 shares of the company’s stock worth $4,330,000 after purchasing an additional 360,800 shares during the period. Prescott Group Capital Management L.L.C. acquired a new stake in WAVE Life Sciences during the 4th quarter worth approximately $1,530,000. F m Investments LLC boosted its stake in WAVE Life Sciences by 24.5% in the 4th quarter. F m Investments LLC now owns 395,894 shares of the company’s stock valued at $6,730,000 after purchasing an additional 77,807 shares during the period. Finally, Elmind Capital LP bought a new stake in WAVE Life Sciences in the 4th quarter valued at $7,613,000. 89.73% of the stock is owned by institutional investors.

WAVE Life Sciences Company Profile

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.